Shares of McKesson Co. (NYSE:MCK) have been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $209.18.
A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft increased their price target on McKesson from $231.00 to $237.00 and gave the stock a “buy” rating in a report on Friday, May 7th. Argus upgraded McKesson from a “hold” rating to a “buy” rating and set a $230.00 target price for the company in a report on Tuesday, March 30th. Credit Suisse Group raised their target price on McKesson from $192.00 to $222.00 and gave the company a “neutral” rating in a report on Monday, May 10th. Mizuho raised their target price on McKesson from $190.00 to $205.00 and gave the company a “neutral” rating in a report on Wednesday, May 12th. Finally, The Goldman Sachs Group raised their target price on McKesson from $231.00 to $257.00 and gave the company a “buy” rating in a report on Friday, May 7th.
In related news, EVP Thomas L. Rodgers sold 145 shares of the firm’s stock in a transaction that occurred on Tuesday, June 1st. The stock was sold at an average price of $189.56, for a total transaction of $27,486.20. Following the transaction, the executive vice president now owns 12,910 shares in the company, valued at approximately $2,447,219.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Brian S. Tyler sold 5,511 shares of the firm’s stock in a transaction that occurred on Thursday, April 15th. The stock was sold at an average price of $191.41, for a total value of $1,054,860.51. Following the transaction, the chief executive officer now owns 24,501 shares in the company, valued at approximately $4,689,736.41. The disclosure for this sale can be found here. Insiders have sold a total of 19,060 shares of company stock worth $3,752,010 in the last three months. Corporate insiders own 0.28% of the company’s stock.
NYSE:MCK traded down $0.23 during trading hours on Friday, hitting $195.28. The company had a trading volume of 13,881 shares, compared to its average volume of 1,056,485. The company has a current ratio of 1.03, a quick ratio of 0.59 and a debt-to-equity ratio of 82.70. The business’s 50-day moving average price is $193.79. The firm has a market capitalization of $30.89 billion, a P/E ratio of -6.83, a P/E/G ratio of 1.47 and a beta of 0.88. McKesson has a 1 year low of $139.76 and a 1 year high of $204.66.
McKesson (NYSE:MCK) last released its quarterly earnings results on Thursday, May 6th. The company reported $5.05 earnings per share for the quarter, topping analysts’ consensus estimates of $5.02 by $0.03. The business had revenue of $59.10 billion during the quarter, compared to analysts’ expectations of $61.08 billion. McKesson had a positive return on equity of 95.80% and a negative net margin of 1.91%. The company’s revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $4.27 EPS. On average, equities analysts expect that McKesson will post 19.21 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 1st. Stockholders of record on Tuesday, June 1st will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, May 31st. McKesson’s dividend payout ratio (DPR) is presently 9.76%.
McKesson Company Profile
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.